Tyra Biosciences Inc.

10.03
0.56 (5.91%)
At close: Apr 23, 2025, 3:59 PM
9.13
-8.97%
Pre-market: Apr 24, 2025, 04:03 AM EDT

Company Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.

Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.

The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers.

In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots.

Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Tyra Biosciences Inc.
Tyra Biosciences Inc. logo
Country United States
IPO Date Sep 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 60
CEO Dr. Todd Harris Ph.D.

Contact Details

Address:
2656 State Street
Carlsbad, California
United States
Website https://www.tyra.bio

Stock Details

Ticker Symbol TYRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001863127
CUSIP Number 90240B106
ISIN Number US90240B1061
Employer ID 83-1476348
SIC Code 2834

Key Executives

Name Position
Dr. Todd Harris Ph.D. Co-Founder, President, Chief Executive Officer, Secretary, Treasurer & Director
Ali D. Fawaz J.D. General Counsel
Amy Conrad Investor Contact
Dr. Douglas Warner M.D. Chief Medical Officer
Dr. Ralph William Charlton III, M.D. Senior Vice President of Clinical Development
Erik Goluboff Senior Vice President of Clinical Development
Liz Pagano Senior Vice President of Human Resources
Sarah Honig Senior Vice President of Corporate Development & Strategy
Sinette Heys Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Apr 18, 2025 ARS Filing
Apr 18, 2025 DEFA14A Filing
Apr 18, 2025 DEF 14A Filing
Mar 31, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Mar 18, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 06, 2025 SCHEDULE 13G Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing